Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19

Journal of Molecular and Cellular Cardiology(2020)10.1016/j.yjmcc.2020.12.009Source: DataRank Database

Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19 is a research paper published in Journal of Molecular and Cellular Cardiology (2020). On theSindex it has a DataRank of 0. It has been cited 18 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

Linked data & code

eudract nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.37)OA: bronzeTopics (54)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Malik Bisserier ORCID,Agnieszka Brojakowska ORCID,Abrisham Eskandari ORCID,Kenneth Fish ORCID,David A. Goukassian ORCID

Live enrichment

PubMed:33373644 PMC:PMC7833205 OpenAlex:https://openalex.org/W3115381124

American Heart Association

Grant: 18IPA34170321

American Heart Association

Grant: 5T32HL007824-22

Training Program in Molecular and Cellular Cardiology

National Institutes of Health

Grant: R01 HL133554

NHLBI NIH HHS

Grant: R01 HL158998

NHLBI NIH HHS

Grant: T32 HL007824

National Institutes of Health

Grant: 3R01HL133554-03S1

Combination Gene Therapy in Combating Pulmonary Arterial Hypertension

FWCI

0.37

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

bronzeLicense: Elsevier TDM

journalhttp://www.jmcc-online.com/article/S0022282820303497/pdf

publisherhttp://www.jmcc-online.com/article/S0022282820303497/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0022282820303497?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022282820303497?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.yjmcc.2020.12.009

Fields of Study

COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research0301 basic medicine03 medical and health sciences0302 clinical medicineCOVID-19Cardiovascular DiseasesDisease ManagementGlobal HealthHumansLung DiseasesSARS-CoV-2United States

MeSH Terms

COVID-19SARS-CoV-2Cardiovascular DiseasesHumansLung DiseasesUnited StatesGlobal HealthDisease Management

Keywords

Coronavirus disease 2019 (COVID-19)MedicinePathophysiologyEpidemiologyCoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseIntensive care medicine2019-20 coronavirus outbreakTransmission (telecommunications)Presentation (obstetrics)Respiratory diseasePathologyInternal medicineOutbreakInfectious disease (medical specialty)LungSurgeryPhysiopathologyTreatmentClinical featuresCovid-19Lung DiseasesSARS-CoV-2Disease ManagementGlobal HealthArticleUnited StatesCardiovascular DiseasesHumansCardiology and Cardiovascular MedicineMolecular Biology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19

FAIR Checklist

Authors (7)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)